Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
With this, the company has also beaten the Zacks Consensus Estimate of $1.33 per share. Improved sales due to market recovery, especially in the “Triad (North America, Europe and Japan) along with the positive impact from restructuring efforts, initiated in July 2008, led the improved results.
Consolidated net sales amounted to $1.72 billion, a robust year-over-year increase of 86%, in line with the guidance of achieving a sales growth of more than 70%. Consequently, organic sales (i.e., sales excluding currency effects and acquisitions/divestitures) grew 64%, better than Autoliv’s guidance of an organic sales increase of “more than 50% for the quarter. This was attributable to strong sales growth in the Triad as well as in China and South Korea.
Segment Performance
Sales of Airbag Products increased a staggering 95% to $1.15 billion, with a 71% rise in organic sales. This was attributable to new business with GM ([url=http://www.zacks.com/stock/quote/mtlqq]MTLQQ[/url]), Ford ([url=http://www.zacks.com/stock/quote/f]F[/url]), Hyundai, Kia and a strong sales recovery in Japan, especially with Toyota ([url=http://www.zacks.com/stock/quote/tm]TM[/url]), Mitsubishi, Nissan ([url=http://www.zacks.com/stock/quote/nsany]NSANY[/url]) and Honda ([url=http://www.zacks.com/stock/quote/hmc]HMC[/url]).
Sales of Seatbelt Products rose 69% to $575 million, with a 51% growth in organic sales. This was driven by new business with Ford, GM, and Hyundai as well as strong sales recoveries, especially with Renault, Daimler ([url=http://www.zacks.com/stock/quote/dai]DAI[/url]), Citroën and Mitsubishi.
Regional Performance
Sales in Europe went up 46% to $730 million, with a 29% rise in organic sales. The strong performance reflected recovery in European light vehicle production, new business for Opel Astra and strong demand for the Peugeot 206+, the Renault Mégane and the Mercedes E-class models.
Sales in North America leapt 138% to $486 million with a 100% growth in organic sales. This was attributable to a favorable vehicle mix and a strong rise in production volumes of Ford’s F-series and E-Series; and of Chevrolet’s Equinox, Traverse and Silverado.
Sales in Japan jacked up 128% to $193 million, with a 116% rise in organic sales. This reflected a strong recovery in the production of premium cars, SUVs and other exported vehicles with high safety content for the North American and West European markets along with new business for Toyota’s Prius 2010 and Alphard; and Honda’s StepWagon.
Sales in Rest of the World shot up 124% to $312 million, with a 104% growth in organic sales. The strong performance reflected organic sales increases of 137% in China, 44% in India and 110% in South Korea. This included new business for Chinese customers such as Geely’s Emgrand EC7, Great Wall’s CoolBear, Florid and Hover; Chery’s A5 and S18; FAW’s Besturn; Jianghuai’s Rein; Citroën’s C5; and Peugeot’s 408. In India, Autoliv benefited from new business with Maruti Suzuki’s Alto and Hyundai’s i10.
Financial Position
Autoliv had cash and cash equivalents of $302 million as of March 31, 2010, compared to $935.4 million in the year-ago period. Long-term debt reduced significantly to $792.5 million from $1.75 billion as of March 31, 2009. The long-term debt-to-capitalization ratio stood at 24% as of March 31, 2010.
In the quarter, cash flow from operations increased to $148.9 million from an outflow of $8.8 million a year ago, due primarily to an improvement in net income. Capital expenditures (net) stood at $36.1 million in the quarter compared to $33.7 million in the prior-year quarter.
Outlook
Autoliv’s consolidated sales are expected to grow more than 40% in the second quarter and about 30% to $6.6 billion for the year. Organic sales are expected to grow at least 30% during the upcoming quarter and 20% during 2010.
Read the full Analyst Report on ALV
Read the full Analyst Report on F
Read the full Analyst Report on TM
Read the full on NSANY
Read the full Analyst Report on HMC